Natera Inc
NASDAQ:NTRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Natera Inc
NASDAQ:NTRA
|
US |
|
Coast Entertainment Holdings Ltd
F:MD8
|
AU |
|
Ithaca Energy PLC
F:XE3
|
UK |
|
A
|
APTIV PLC
F:D7A
|
CH |
|
A
|
AES Corp
F:AES
|
US |
Intrinsic Value
Is NTRA undervalued or overvalued?
See the intrinsic value estimate for Natera Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Natera Does
Natera is a genetic testing company that analyzes DNA from blood, saliva, or tissue samples to help doctors make medical decisions. Its main products are tests for prenatal screening, hereditary cancer risk, and transplant monitoring, along with tests that help guide care for people with certain cancers. The company sells these tests to hospitals, doctors, cancer centers, and specialty clinics, and it makes money when those tests are ordered and processed.
- Headquarters
- United States of America US
- Employees
- 6 135
- IPO date
- Jul 2, 2015
Natera has a narrow economic moat
Patents protect parts of Natera’s genetic testing methods, while approval to guide a specific bladder cancer treatment gives Signatera a role that rivals cannot simply copy. Its patient-specific test setup also gives doctors a practical reason to keep ongoing monitoring with Natera. These protections apply most clearly to cancer testing rather than equally across all its markets.
Read the full moat analysis
Revenue & Expenses Breakdown
Natera Inc
Earnings Waterfall
Natera Inc
The intrinsic value for Natera Inc (NTRA) under the Base Case is hidden USD.
Compared with the current market price of 413.275 USD, the stock appears hidden.